Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025
Organogenesis Holdings (Nasdaq: ORGO), a regenerative medicine company specializing in Advanced Wound Care and Surgical and Sports Medicine markets, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.
Management will conduct a conference call at 5:00 p.m. Eastern Time on the same day to discuss quarterly results and provide a corporate update, followed by a Q&A session. The event will be accessible via webcast through the company's investor relations website, where it will remain archived for approximately one year.
Organogenesis Holdings (Nasdaq: ORGO), una società di medicina rigenerativa specializzata nei mercati della cura avanzata delle ferite e della medicina chirurgica e sportiva, ha programmato l'annuncio dei suoi risultati finanziari del primo trimestre 2025 per il 8 maggio 2025, dopo la chiusura del mercato.
La direzione condurrà una conferenza telefonica alle 17:00 ora orientale dello stesso giorno per discutere i risultati trimestrali e fornire un aggiornamento aziendale, seguita da una sessione di domande e risposte. L'evento sarà accessibile tramite webcast attraverso il sito web delle relazioni con gli investitori dell'azienda, dove rimarrà archiviato per circa un anno.
Organogenesis Holdings (Nasdaq: ORGO), una empresa de medicina regenerativa especializada en los mercados de Cuidado Avanzado de Heridas y Medicina Quirúrgica y Deportiva, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 8 de mayo de 2025, después del cierre del mercado.
La dirección llevará a cabo una conferencia telefónica a las 5:00 p.m. Hora del Este el mismo día para discutir los resultados trimestrales y proporcionar una actualización corporativa, seguida de una sesión de preguntas y respuestas. El evento será accesible a través de un webcast en el sitio web de relaciones con inversores de la empresa, donde permanecerá archivado durante aproximadamente un año.
Organogenesis Holdings (Nasdaq: ORGO)는 고급 상처 치료 및 외과 및 스포츠 의학 시장을 전문으로 하는 재생 의학 회사로, 2025년 1분기 재무 결과 발표를 2025년 5월 8일 시장 마감 후로 예정하고 있습니다.
경영진은 같은 날 동부 표준시 오후 5시에 분기 결과를 논의하고 기업 업데이트를 제공하기 위한 컨퍼런스 콜을 진행하며, 이후 질의응답 세션이 이어질 것입니다. 이 행사는 회사의 투자자 관계 웹사이트를 통해 웹캐스트로 접근 가능하며, 약 1년 동안 아카이브로 남아 있을 것입니다.
Organogenesis Holdings (Nasdaq: ORGO), une entreprise de médecine régénérative spécialisée dans les marchés des soins avancés des plaies et de la médecine chirurgicale et sportive, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le 8 mai 2025, après la clôture du marché.
La direction tiendra une conférence téléphonique à 17h00, heure de l'Est le même jour pour discuter des résultats trimestriels et fournir une mise à jour de l'entreprise, suivie d'une session de questions-réponses. L'événement sera accessible par webcast via le site web des relations avec les investisseurs de l'entreprise, où il restera archivé pendant environ un an.
Organogenesis Holdings (Nasdaq: ORGO), ein Unternehmen für regenerative Medizin, das sich auf die Märkte für fortschrittliche Wundversorgung sowie chirurgische und Sportmedizin spezialisiert hat, hat die Bekanntgabe seiner Finanzergebnisse für das erste Quartal 2025 für den 8. Mai 2025, nach Börsenschluss, angesetzt.
Das Management wird am selben Tag um 17:00 Uhr Eastern Time eine Telefonkonferenz durchführen, um die Quartalsergebnisse zu besprechen und ein Unternehmensupdate zu geben, gefolgt von einer Q&A-Session. Die Veranstaltung wird über einen Webcast auf der Investor-Relations-Website des Unternehmens zugänglich sein, wo sie etwa ein Jahr lang archiviert bleibt.
- None.
- None.
CANTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that first quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, May 8th.
Management will host a conference call at 5:00 p.m. Eastern Time on May 8th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.
Investor Inquiries: ICR Healthcare Mike Piccinino, CFA OrganoIR@icrinc.com Press and Media Inquiries: Organogenesis communications@organo.com
FAQ
When will Organogenesis (ORGO) release Q1 2025 earnings?
How can investors access ORGO's Q1 2025 earnings call?
What markets does Organogenesis (ORGO) operate in?
How long will ORGO's Q1 2025 earnings webcast be available?
